Raja Kandaswamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raja Kandaswamy has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- David Michael Vock
University of Minnesota
5 shared publications - Arthur J. Matas
Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, USA
4 shared publications - Oscar Kenneth Serrano
Hartford Hospital
4 shared publications - Ty Blink Dunn
Medical College of Wisconsin, Milwaukee, USA
4 shared publications - Angelika C. Gruessner
Department of Medicine, Division of Nephrology, SUNY Downstate University of Health Sciences, Brooklyn, NY
3 shared publications - Erik B. Finger
Department of Surgery, University of Minnesota
3 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (3) , 587-595
A 100-year simulation of the National Kidney Registry’s voucher program
- 21 November 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (3) , 587-595
Open AccessA 100-year simulation of the National Kidney Registry’s voucher program
- Open Access
- 15 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (7)
Estimated Glomerular Filtration Rate Less Than 90 mL/min/1.73m2 in Living Donor Candidates Under 30 Years Old and Long‐Term Outcomes
Background: Traditionally, glomerular filtration rate (GFR) ≥80 mL/min/1.73 m2 has been the threshold for living kidney donor (LKDs) acceptance. Recently, the threshold has been lowered for older donors. There is consideration of raising it for younger donors.Methods: We compared long‐term outcomes for LKDs age 18–29 with predonation eGFR < 90 to those with eGFR ≥ 90. LKDs with eGFR p < 0.001) to a first degree relative (86.7% vs. 75.3%, p = 0.008) and have a family history of diabetes (53.8% vs. 40.6%, p = 0.009). During a median follow‐up of 25 [12, 37] years no associations were detected between low predonation eGFR and death, eGFR < 45, hypertension, diabetes, or CVD. Results among LKDs age < 25 were similar.Conclusions: Our data do not support increasing the eGFR threshold among young White non‐Hispanic donor candidates, reducing one barrier to living donation.
- 15 July 2025
- Published by Wiley in Clinical Transplantation
- Vol. 39 (7)
Open AccessEstimated Glomerular Filtration Rate Less Than 90 mL/min/1.73m2 in Living Donor Candidates Under 30 Years Old and Long‐Term Outcomes
Background: Traditionally, glomerular filtration rate (GFR) ≥80 mL/min/1.73 m2 has been the threshold for living kidney donor (LKDs) acceptance. Recently, the threshold has been lowered for older donors. There is consideration of raising it for younger donors.Methods: We compared long‐term outcomes for LKDs age 18–29 with predonation eGFR < 90 to those with eGFR ≥ 90. LKDs with eGFR p < 0.001) to a first degree relative (86.7% vs. 75.3%, p = 0.008) and have a family history of diabetes (53.8% vs. 40.6%, p = 0.009). During a median follow‐up of 25 [12, 37] years no associations were detected between low predonation eGFR and death, eGFR < 45, hypertension, diabetes, or CVD. Results among LKDs age < 25 were similar.Conclusions: Our data do not support increasing the eGFR threshold among young White non‐Hispanic donor candidates, reducing one barrier to living donation.
- 4 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15448
Small Donors, Big Impact: Optimizing Organ Utilization in Simultaneous Pancreas and Kidney Transplantation From Extra Small Pediatric Donors
Introduction: Simultaneous pancreas–kidney transplantation (SPK) is the preferred treatment for individuals with type‐1 diabetes and end‐stage renal disease. However, a limited supply of “Ideal Pancreas Donors” contributed to a growing disparity between available organs and recipients. Even though SPK outcomes from pediatric donors match those from adult donors, unclear guidelines on minimum age and weight criteria for extra small pediatric pancreas donors lead to hesitancy among several transplant centers to utilize these grafts due to concerns about inadequate islet mass, technical challenges, and increased risk of allograft thrombosis.Methods: This report details the successful outcomes of SPK transplantations performed at the study center between December 2021 and January 2024, using four extra small pediatric brain‐dead donors (ESPDs). Each donor was aged ≤5 years and weighed <20 kg.Results: All SPK recipients achieved immediate posttransplant euglycemia without requiring insulin. None of the recipients experienced graft pancreatitis, graft thrombosis, allograft rejection, or required re‐exploration. During a 5–27‐month follow‐up period, all ESPD recipients maintained optimal graft function, as evidenced by normal glucose tolerance tests and HbA1c (4.9%–5.2%), with 100% graft and patient survival.Conclusion: This report examines the usage of ESPDs in SPK transplantation, highlighting their potential to expand the donor pool and reduce wait times in areas with scarce deceased organ donations, thereby increasing the number of available organs for transplantation with acceptable outcomes. Revising donor selection guidelines to reflect the diverse risk–benefit profiles of waitlisted individuals is crucial to addressing geographical disparities and reducing organ discard rates.
- 4 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15448
Small Donors, Big Impact: Optimizing Organ Utilization in Simultaneous Pancreas and Kidney Transplantation From Extra Small Pediatric Donors
Introduction: Simultaneous pancreas–kidney transplantation (SPK) is the preferred treatment for individuals with type‐1 diabetes and end‐stage renal disease. However, a limited supply of “Ideal Pancreas Donors” contributed to a growing disparity between available organs and recipients. Even though SPK outcomes from pediatric donors match those from adult donors, unclear guidelines on minimum age and weight criteria for extra small pediatric pancreas donors lead to hesitancy among several transplant centers to utilize these grafts due to concerns about inadequate islet mass, technical challenges, and increased risk of allograft thrombosis.Methods: This report details the successful outcomes of SPK transplantations performed at the study center between December 2021 and January 2024, using four extra small pediatric brain‐dead donors (ESPDs). Each donor was aged ≤5 years and weighed <20 kg.Results: All SPK recipients achieved immediate posttransplant euglycemia without requiring insulin. None of the recipients experienced graft pancreatitis, graft thrombosis, allograft rejection, or required re‐exploration. During a 5–27‐month follow‐up period, all ESPD recipients maintained optimal graft function, as evidenced by normal glucose tolerance tests and HbA1c (4.9%–5.2%), with 100% graft and patient survival.Conclusion: This report examines the usage of ESPDs in SPK transplantation, highlighting their potential to expand the donor pool and reduce wait times in areas with scarce deceased organ donations, thereby increasing the number of available organs for transplantation with acceptable outcomes. Revising donor selection guidelines to reflect the diverse risk–benefit profiles of waitlisted individuals is crucial to addressing geographical disparities and reducing organ discard rates.
- Open Access
- 21 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 362-379
Banff 2022 pancreas transplantation multidisciplinary report: Refinement of guidelines for T cell–mediated rejection, antibody-mediated rejection and islet pathology. Assessment of duodenal cuff biopsies and noninvasive diagnostic methods
- 21 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (3) , 362-379
Open AccessBanff 2022 pancreas transplantation multidisciplinary report: Refinement of guidelines for T cell–mediated rejection, antibody-mediated rejection and islet pathology. Assessment of duodenal cuff biopsies and noninvasive diagnostic methods
- Open Access
- 23 May 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (9) , e15036
Protocolized screening and detection of occult alcohol use before and after liver transplant: Lessons learned from a quality improvement initiative
Detection of alcohol (ETOH) use with biomarkers provides an opportunity to intervene and treat patients with alcohol use disorder before and after liver transplant (LT). We describe our center's experience using urine ethyl glucuronide (EtG) and serum phosphatidylethanol (PEth) in alcohol screening protocols. Single-center, retrospective review of patients presenting for LT evaluation, patients waitlisted for LT for alcohol-associated liver disease (ALD), and patients who received a LT for ALD over a 12-month period, from October 1, 2019 through September 30, 2020. Patients were followed from waitlisting to LT, or for up to 12 months post-LT. We monitored protocol adherence to screening for ETOH use- defined as completion of all possible tests over the follow-up period- at the initial LT visit, while on the LT waitlist and after LT. During the study period, 227 patients were evaluated for LT (median age 57 years, 58% male, 78% white, 54.2% ALD). Thirty-one patients with ALD were placed on the waitlist, and 38 patients underwent LT for ALD during this time period. Protocolized adherence to screening for alcohol use was higher for PEth for all LT evaluation patients (191 [84.1%] vs. 146 [67%] eligible patients, p < .001), in patients with ALD waitlisted for LT (22 [71%] vs. 14 (48%] eligible patients, p = .04) and after LT for ALD, 20 (33 [86.8%] vs. 20 [52.6%] eligible patients, p < .01). Few patients with a positive test in any group completed chemical dependency treatment. When screening for ETOH use in pre- and post-LT patients, protocol adherence is higher using PEth compared to EtG. While protocolized biomarker screening can detect recurrent ETOH use in this population, engagement of patients into chemical dependency treatment remains challenging.
- 23 May 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (9) , e15036
Open AccessProtocolized screening and detection of occult alcohol use before and after liver transplant: Lessons learned from a quality improvement initiative
Detection of alcohol (ETOH) use with biomarkers provides an opportunity to intervene and treat patients with alcohol use disorder before and after liver transplant (LT). We describe our center's experience using urine ethyl glucuronide (EtG) and serum phosphatidylethanol (PEth) in alcohol screening protocols. Single-center, retrospective review of patients presenting for LT evaluation, patients waitlisted for LT for alcohol-associated liver disease (ALD), and patients who received a LT for ALD over a 12-month period, from October 1, 2019 through September 30, 2020. Patients were followed from waitlisting to LT, or for up to 12 months post-LT. We monitored protocol adherence to screening for ETOH use- defined as completion of all possible tests over the follow-up period- at the initial LT visit, while on the LT waitlist and after LT. During the study period, 227 patients were evaluated for LT (median age 57 years, 58% male, 78% white, 54.2% ALD). Thirty-one patients with ALD were placed on the waitlist, and 38 patients underwent LT for ALD during this time period. Protocolized adherence to screening for alcohol use was higher for PEth for all LT evaluation patients (191 [84.1%] vs. 146 [67%] eligible patients, p < .001), in patients with ALD waitlisted for LT (22 [71%] vs. 14 (48%] eligible patients, p = .04) and after LT for ALD, 20 (33 [86.8%] vs. 20 [52.6%] eligible patients, p < .01). Few patients with a positive test in any group completed chemical dependency treatment. When screening for ETOH use in pre- and post-LT patients, protocol adherence is higher using PEth compared to EtG. While protocolized biomarker screening can detect recurrent ETOH use in this population, engagement of patients into chemical dependency treatment remains challenging.
- Open Access
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S36
214.5: Long-term Outcomes in Primary Simultaneous Kidney and Pancreas Recipients Under Steroid Avoidance in the United States
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S36
Open Access214.5: Long-term Outcomes in Primary Simultaneous Kidney and Pancreas Recipients Under Steroid Avoidance in the United States
- Open Access
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S328
343.3: Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States
- 13 September 2022
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (9S) , S328
Open Access343.3: Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States
- Open Access
- 10 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (Suppl 3) , 17-59
First World Consensus Conference on pancreas transplantation: Part II – recommendations
- 10 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (Suppl 3) , 17-59
Open AccessFirst World Consensus Conference on pancreas transplantation: Part II – recommendations
- Open Access
- 9 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (Suppl 3) , 1-16
First world consensus conference on pancreas transplantation: Part I—Methods and results of literature search
- 9 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (Suppl 3) , 1-16
Open AccessFirst world consensus conference on pancreas transplantation: Part I—Methods and results of literature search